Please assess the completion status of the following clinical trial:

Trial Title: Inhaled GM-CSF Therapy of Autoimmune PAP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female of male 18 years of age or older~* Diagnosis of autoimmune PAP~* Able and willing to provide written informed consent~* Eligible for whole lung lavage determined as the presence of persistent or progressive respiratory failure (PaO2 at rest \< 60 mm Hg) or desaturation \< 90% or \> 5 percentage points during standard exercise~Exclusion Criteria:~* Diagnosis with secondary PAP, congenital PAP, or hereditary PAP~* Contraindication to whole lung lavage~* Contraindication to administration of inhaled GM-CSF~* Chronic lung disease associated with already existing respiratory failure, such as emphysema or pulmonary fibrosis, chronic heart failure, ischemic heart disease, active pulmonary embolism, progressive cancer, and other severe metabolic conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GM-CSF Group (Type: EXPERIMENTAL): Scheduled Baseline WLL: All participants will receive scheduled bilateral WLL at baseline (month 0).~GM-CSF induction treatment: All participants will receive inhaled GM-CSF (250 mcg daily, 7 consecutive days every other week for 12 weeks beginning 1 week after the scheduled baseline WLL).~Washout period: All participants will not receive inhaled GM-CSF treatment for 4 weeks immediately following GM-CSF induction treatment.~GM-CSF maintenance treatment: All participants will receive inhaled GM-CSF (250 mcg daily on days 1 and 3 of every consecutive 14-day period for 6 months beginning 17 weeks after the scheduled baseline WLL).~Unscheduled Rescue WLL: Any participant experiencing progression of aPAP lung disease (defined as the disease progression resulting in respiratory failure (PaO2 at rest \<60 mmHg of PaO2 \> 60 mmHg at rest AND desaturation \<90% at rest OR decline in SpO2 of 5% or more during exercise testing) will receive unscheduled rescue WLL.
- Control Group (Type: OTHER): Scheduled Baseline WLL: All participants will receive a scheduled bilateral WLL at baseline (month 0).~Unscheduled Rescue WLL: Any participant experiencing progression of aPAP lung disease (defined as the disease progression resulting in respiratory failure (defined by a resting PaO2 \<60 mmHg or \> 60 mmHg and desaturation \<90% at rest or decline in SpO2 of 5% or more during exercise testing) will receive unscheduled rescue WLL.

Based on this trial design, predict the completion outcome and termination type (if applicable).